
Newpath Partners kicks off $350M fund with a wunderkind holding the bag and an all-star scientific team waiting in the wings
The world of biotech isn’t short on big personalities, but it’s not exactly common to see young professionals earning the broad respect of seasoned academics. Yet, Tom Cahill and his team at Newpath have snagged the support of some of biotech’s biggest names in just a few short years in existence.
How did Cahill do it? He thinks big.
Newpath Partners kicked off its second venture fund Wednesday, dubbed Newpath Fund II, with $350 million to support research from some of the best and brightest researchers and serial biotech entrepreneurs waiting in the wings.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters